Published 2022
| Version v1
Journal article
No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?
Creators
- Fayet, Yohan
- Chevreau, Christine
- Decanter, Gauthier
- Dalban, Cécile
- Méeus, Pierre
- Carrere, Sebastien
- Haddag-Miliani, Leïla
- Le Loarer, François
- Causeret, Sylvain
- Orbach, Daniel
- Kind, Michelle
- Le Nail, Louis-Romée
- Ferron, Gwénaël
- Labrosse, Hélène
- Chaigneau, Loïc
- Bertucci, François
- Ruzic, Jean-Christophe
- Le Brun-Ly, Valérie
- Farsi, Fadila
- Bompas, Emmanuelle
- Noal, Sabine
- Vozy, Aurore
- Ducoulombier, Agnès
- Bonnet, Clement
- Chabaud, Sylvie
- Ducimetière, Françoise
- Tlemsani, Camille
- Ropars, Mickael
- Collard, Olivier
- Michelin, Paul
- Gantzer, Justine
- Dubray-Longeras, Pascale
- Rios, Maria
- Soibinet-Oudot, Pauline
- Le Cesne, Axel
- Duffaud, Florence
- Karanian, Marie
- Gouin, Francois
- Tetreau, Raphaël
- Honoré, Charles
- Coindre, Jean-Michel
- Ray-Coquard, Isabelle
- Bonvalot, Sylvie
- Blay, Jean-Yves
Contributors
Others:
- Centre Léon Bérard [Lyon]
- Research on Healthcare Performance (RESHAPE - Inserm U1290 - UCBL1) ; Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille) ; Université de Lille-UNICANCER
- Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM) ; CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Institut Gustave Roussy (IGR)
- Département de médecine oncologique [Gustave Roussy] ; Institut Gustave Roussy (IGR)
- Institut Bergonié [Bordeaux] ; UNICANCER
- Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
- Institut Curie [Paris]
- CHU Trousseau [Tours] ; Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Université de Tours (UT)
- Centre de Recherches en Cancérologie de Toulouse (CRCT) ; Université Toulouse III - Paul Sabatier (UT3) ; Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Institut Claudius Regaud
- Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Institut Paoli-Calmettes ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
- CHU Sud Saint Pierre [Ile de la Réunion]
- Hôpital Dupuytren [CHU Limoges]
- Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO) ; UNICANCER
- Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC) ; Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
- CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Institut Universitaire de Cancérologie [Paris] (IUC) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
- Galilée (Galilée) ; Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Hopital Saint-Louis [AP-HP] (AP-HP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Cancer Research and Personalized Medicine - CARPEM [Paris] ; Hôpital Européen Georges Pompidou [APHP] (HEGP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Institut Cochin (IC UM3 (UMR 8104 / U1016)) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
- CHU Pontchaillou [Rennes]
- Université de Rennes 1 (UR1) ; Université de Rennes (UNIV-RENNES)
- Hôpital privé de la Loire
- Hôpital Charles Nicolle [Rouen]
- Institut de Cancérologie de Strasbourg Europe (ICANS)
- Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP) ; UNICANCER
- Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL) ; UNICANCER
- Centre Hospitalier Universitaire de Reims (CHU Reims)
- Aix Marseille Université (AMU)
- Hôpital de la Timone [CHU - APHM] (TIMONE)
- CHU Lyon
- Institut du Cancer de Montpellier (ICM)
- Pôle chirurgical et interventionnel [Gustave Roussy] ; Institut Gustave Roussy (IGR)
- Université Paris sciences et lettres (PSL)
- ARC Foundation [PGA1*20160203865]; INCA (French National Cancer Institute) [SHSESP16-063]; SIRIC LYriCAN [INCa-DGOS-Inserm_12563]; INCa; DGOS; EURACAN European Reference Network [EC 739521]
Description
Simple Summary As patients with rare cancers face specific problems, reference networks have been developed in several European countries and then at the European level to improve their management. In some cases, the specialized centers belonging to reference networks provide remote services (specialized diagnosis review, discussion in the Multidisciplinary Tumour Board, etc.) to increase access to these services. Using data from the national sarcoma reference network implemented in France (NETSARC+), the IGeAS research program assesses the potential of its organization to address the geographical inequalities in cancer management. We analyze the individual, clinical, and geographical determinants of the overall survival of sarcoma patients in France. We found no association between the overall survival of sarcoma patients and variables measuring their social deprivation, remoteness from reference centers, and geographical context. Following previous results from the research program, this study suggests that reference network organization should be considered to reduce cancer inequalities. The national reference network NETSARC+ provides remote access to specialized diagnosis and the Multidisciplinary Tumour Board (MTB) to improve the management and survival of sarcoma patients in France. The IGeAS research program aims to assess the potential of this innovative organization to address geographical inequalities in cancer management. Using the IGeAS cohort built from the nationwide NETSARC+ database, the individual, clinical, and geographical determinants of the 3-year overall survival of sarcoma patients in France were analyzed. The survival analysis was focused on patients diagnosed in 2013 (n = 2281) to ensure sufficient hindsight to collect patient follow-up. Our study included patients with bone (16.8%), soft-tissue (69%), and visceral (14.2%) sarcomas, with a median age of 61.8 years. The overall survival was not associated with geographical variables after adjustment for individual and clinical factors. The lower survival in precarious population districts [HR 1.23, 95% CI 1.02 to 1.48] in comparison to wealthy metropolitan areas (HR = 1) found in univariable analysis was due to the worst clinical presentation at diagnosis of patients. The place of residence had no impact on sarcoma patients' survival, in the context of the national organization driven by the reference network. Following previous findings, this suggests the ability of this organization to go through geographical barriers usually impeding the optimal management of cancer patients.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.archives-ouvertes.fr/hal-03718397
- URN
- urn:oai:HAL:hal-03718397v1
Origin repository
- Origin repository
- UNICA